<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">17565850</PMID>
        <DateCreated>
            <Year>2007</Year>
            <Month>06</Month>
            <Day>13</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2008</Year>
            <Month>10</Month>
            <Day>21</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2011</Year>
            <Month>11</Month>
            <Day>17</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0376-2491</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>87</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2007</Year>
                        <Month>Mar</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Zhonghua yi xue za zhi</Title>
                <ISOAbbreviation>Zhonghua Yi Xue Za Zhi</ISOAbbreviation>
            </Journal>
            <ArticleTitle>[Cytotoxicity of dendritic cells pulsed by CpG ODN on ovarian carcinoma cells: in vitro experiment with ovarian carcinoma cells].</ArticleTitle>
            <Pagination>
                <MedlinePgn>778-82</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate the effect of dendritic cells (DCs) pulsed by oligonucleotide containing &quot;un-methylated cytimidine-phosphodiester bond-guanylic acid&quot; motif (CpG ODN) on ovarian carcinoma cells.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Dendritic cells were isolated form the peripheral monocytes and co-incubated with synthesized CpG2006, CAI125, important epithelial ovarian cancer-associated antigen, or CpG ODN + CA125 for 72 h. Flow cytometry (FC) was used to detect the expression of CD(1alpha), CD(63), CD(86), and human leucocyte antigen-DR (HLA-DR) on the cell surface. ELISA was used to detect the IL-12 level in the supernatant. T cells were obtained from the DCs. The suspensions of different groups of pulsed DCs were co-incubated with T cells. Mixed lymphocyte reaction (MLR) was used to detect the proliferating activity of the T cells. Ovarian carcinoma cells of the line OVCAR-3 were added into the culture fluid of T cells with different effector-target ratios, and then unpulsed DCs, CpG ODN-pulsed DCs, CpG ODN + CA125-pulsed DCs, and CA125-pulsed DCs were added respectively. MTT colorimetry was performed to measure the A values of different wells so as to calculate the killing rate.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">(1) The expression levels of CD(63), CD(86), and HLA-DR on the membranes of the CpG ODN-pulsed DCs and CpG ODN + C125-pulsed DCs were significantly higher than those of the un-pulsed DCs (all P &lt; 0.01), however, there were no significant differences in the expression of CD(1alpha) among different groups (all P &gt; 0.05). (2) The IL-12 levels in the supernatants of the CpG ODN-pulsed DCs and CpG ODN + C125-pulsed DCs were significantly higher than those of the unpulsed and CA125-pulsed groups (all P &lt; 0.01). (3) MLR showed that the T cell proliferation rates of the T cells sensitized by the CpG ODN-pulsed DCs and CpG ODN + C125-pulsed DCs were both higher than those of the T cells stimulated by the unpulsed and CA125-pulsed groups when the effector: target ratio was 10:1 (all P &lt; 0.01). (4) The killing rates on OVCAR-3 cells of the CTLs sensitized by CpG ODN + CA125-pulsed DCs at the same effector: target ratios were all higher than those of the CTLs sensitized by the CpG ODN-pulsed DCs, CA125-pulsed DCs, and unpulsed DCs (all P &lt; 0.01), the killing activity of the cytotoxic T lymphocytes (CTLs) sensitized by CpG ODN+CA125-pulsed DCs on the OVCAR-3 cells was shown even when the effector: target ratio was as low as 10:1, and then increased along with the increase of the effector: target ratio to the height of 64.9%.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Capable of inducing immune cytotoxicity on ovarian carcinoma, DCs sensitized by CpG ODN + CA125 may have a great implication on clinical application.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ye</LastName>
                    <ForeName>Ming-Zhu</ForeName>
                    <Initials>MZ</Initials>
                    <Affiliation>Department of Obstetrics and Gynecology, Second Hospital of Jilin University, Changchun 130041, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>He-Lian</ForeName>
                    <Initials>HL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Han</LastName>
                    <ForeName>Li-Ying</ForeName>
                    <Initials>LY</Initials>
                </Author>
            </AuthorList>
            <Language>chi</Language>
            <PublicationTypeList>
                <PublicationType>English Abstract</PublicationType>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>China</Country>
            <MedlineTA>Zhonghua Yi Xue Za Zhi</MedlineTA>
            <NlmUniqueID>7511141</NlmUniqueID>
            <ISSNLinking>0376-2491</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>1018 oligonucleotide</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Antigens, CD</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Antigens, CD1</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Antigens, CD63</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Antigens, CD86</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>CA-125 Antigen</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>CD63 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Oligodeoxyribonucleotides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Platelet Membrane Glycoproteins</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Antigens, CD</DescriptorName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Antigens, CD1</DescriptorName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Antigens, CD63</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Antigens, CD86</DescriptorName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">CA-125 Antigen</DescriptorName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
                <QualifierName MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Coculture Techniques</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Cytotoxicity, Immunologic</DescriptorName>
                <QualifierName MajorTopicYN="Y">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Dendritic Cells</DescriptorName>
                <QualifierName MajorTopicYN="N">cytology</QualifierName>
                <QualifierName MajorTopicYN="Y">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Flow Cytometry</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Lymphocyte Culture Test, Mixed</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Oligodeoxyribonucleotides</DescriptorName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
                <QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Platelet Membrane Glycoproteins</DescriptorName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">T-Lymphocytes</DescriptorName>
                <QualifierName MajorTopicYN="N">cytology</QualifierName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2007</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2008</Year>
                <Month>10</Month>
                <Day>22</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2007</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">17565850</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
